摘要:
The present invention relates to a group of compounds with a structural nucleus derived from phenylacetamide, having the following formula (I):
that can modulate the DREAM neuronal calcium sensor. Consequently, the present invention also relates to the use of these compounds for the treatment or prevention of disorders or diseases in which DREAM levels are above or below physiologically normal levels.
摘要:
The invention relates to a polypeptide which comprises the fragment SEQ ID No.: 2 of the peptide GSE 24.2 (SEQ ID No.:1) and can reduce the production of free radicals and/or damage to the DNA structure of a cell, optionally comprising nuclear localisation sequences. The invention also relates to a polynucleotide and to a vector, which comprise sequences coding for said polypeptide, and to a pharmaceutical composition comprising said polypeptide, polynucleotide and/or vector. The invention further relates to the applications of the polypeptide, such as the use thereof for treating and/or preventing diseases caused by an increase in oxidative stress and/or damage to cellular DNA, such as ataxia-telangiectasia or dyskeratosis congenita, or the use thereof in tissue engineering and cell culture for increasing the viability of same.
摘要翻译:本发明涉及包含肽GSE 24.2(SEQ ID No.1)的SEQ ID No.2的片段的多肽,并且可以任选地减少游离基的产生和/或细胞的DNA结构的损伤 包括核定位序列。 本发明还涉及包含编码所述多肽的序列的多核苷酸和载体,以及包含所述多肽,多核苷酸和/或载体的药物组合物。 本发明还涉及多肽的应用,例如其用于治疗和/或预防由氧化应激增加和/或细胞DNA损伤引起的疾病,例如共济失调 - 毛细血管扩张症或先天性角化不全,或使用 在组织工程和细胞培养中增加其生存能力。
摘要:
The invention relates to the use of the insulin-like growth factor (IGF-1) as a reagent for the early diagnosis and/or prognosis of Alzheimer disease, to a kit comprising IGF-1 and a sedative, and to the use thereof in the early diagnosis and/or prognosis of Alzheimer disease.
摘要:
Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. This invention relates to the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, it relates to an adult multipotent cell or a cell population or composition comprising said cell, isolated from non-osteochondral mesenchymal tissue, characterized in that it is positive for the following markers: CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 and because it lacks expression of the following markers: CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 and CD133.